X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Brii will get access to focus on the development of VBI-2601 (BRII-179), a protein-based HBV immunotherapeutic candidate intended for the treatment of chronic HBV infection.
Lead Product(s): BRII-179,Elebsiran
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: VBI Vaccines
Deal Size: $33.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition February 13, 2024
Details:
VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.
Lead Product(s): BRII-179,VIR-2218
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: VBI Vaccines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Under the collaboration, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and acquired an exclusive license for PreHevbri, VBI’s 3-antigen hepatitis B vaccine, in the Asia Pacific region (APAC).
Lead Product(s): BRII-179
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: VBI Vaccines
Deal Size: $437.0 million Upfront Cash: $15.0 million
Deal Type: Expanded Collaboration July 05, 2023
Details:
Brii Bio will acquire exclusive global rights for the development and commercialization of QPX9003 (BRII-693), a novel synthetic lipopeptide in development for the treatment of MDR/XDR gram-negative bacterial infections, to expand from its existing rights in Greater China.
Lead Product(s): BRII-693
Therapeutic Area: Infections and Infectious Diseases Product Name: QPX9003
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Qpex Biopharma
Deal Size: Undisclosed Upfront Cash: $24.0 million
Deal Type: Acquisition June 25, 2023
Details:
BRII-297 is a gamma-aminobutyric acid A receptor positive allosteric modulator and first-of-its-kind long-acting injectable therapeutic candidate in development for the treatment of various anxiety and depressive disorders.
Lead Product(s): BRII-297
Therapeutic Area: Psychiatry/Psychology Product Name: BRII-297
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
BRII-732/BRII-778 combination is currently in Phase 1 development in the U.S. as therapy for human immunodeficiency virus infection that can be administered on weekly basis potentially preferable choice for patients currently receiving once-daily treatment for HIV.
Lead Product(s): Islatravir Prodrug,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Product Name: BRII-732
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Independent lab results demonstrate that the BRII-196 (amubarvimab/romlusevimab) combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date.
Lead Product(s): Amubarvimab,Romlusevimab
Therapeutic Area: Infections and Infectious Diseases Product Name: BRII-196
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
BRII-196 (amubarvimab) and romlusevimab are non-competing SARS-CoV-2 mAB derived from convalesced COVID-19 patients, have been specifically engineered to reduce risk of antibody-dependent enhancement and prolong plasma half-lives for potentially more durable treatment effect.
Lead Product(s): Amubarvimab,Romlusevimab
Therapeutic Area: Infections and Infectious Diseases Product Name: BRII-196
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: TSB Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Studies conducted by independent labs demonstrated the BRII-196 (amubarvimab) in combination with romlusevimab retains neutralizing activity against COVID-19 Omicron variant.
Lead Product(s): Amubarvimab,Romlusevimab
Therapeutic Area: Infections and Infectious Diseases Product Name: BRII-196
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
The data demonstrate that BRII-835 (VIR-2218), an small interfering ribonucleic acid that mediates RNA interference, results in dose-dependent reduction in hepatitis B surface antigen in Chinese patients with chronic HBV infection who received two doses of BRII-835.
Lead Product(s): VIR-2218,BRII-179
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-2218
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
